ArticleJournal of the Endocrine Society2025
Reduced IGF-1 Levels Following Clomiphene Treatment for Male Hypogonadism.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reduced expression of SOCS1-5 and STAT5a genes in Parkinson's disease patients: evidence for dysregulated immune signaling.Molecular biology reports · 2026Article
- Clomiphene Citrate in Men With Hypogonadism-Do we Need to Monitor IGF-1 in All Patients?Journal of the Endocrine Society · 2025Article
- Genetic SHBG Deficiency Unmasks the Discrepancy Between Biochemical and Clinical Hypogonadism.JCEM case reports · 2025Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: The selective estrogen receptor modulator clomiphene stimulates pituitary-derived gonadotropins to generate sex steroids including estrogen. Estrogen activates SOCS-3, which can inhibit growth hormone-directed JAK/STAT signaling to reduce serum insulin-like growth factor (IGF)-1 levels. Objective: We sought to examine the effects of clomiphene therapy on IGF-1 levels in nonacromegalic male patients treated with clomiphene for underlying hypogonadism. Methods: We identified 20 male subjects with hypogonadism treated with clomiphene citrate for at least 3 months. These patients were treated in an ambulatory, academic, tertiary medical center. The 20 male patients ranged from 27 to 76 years of age and hypogonadism was due to several etiologies, including prolactinomas, clinically nonfunctioning pituitary tumors, Rathke cleft cysts, colloid cysts, or idiopathic causes. Clomiphene citrate 50 mg 3 days per week was administered for a minimum of 3 months. IGF-1 was measured by liquid chromatography-mass spectroscopy before and after clomiphene therapy. Results: Fifteen of 20 (75%) of hypogonadal men treated with clomiphene exhibited a decrease in median (IQR) serum IGF-1 levels of -0.60 (-1.2-0.0) ( Conclusion: Clomiphene therapy can result in a significant reduction in serum IGF-1 levels in some treated hypogonadal men. Given that the decrease in IGF-1 can be >2 SD in some patients and potentially clinically significant, we recommend interval monitoring of serum IGF-1 levels and symptoms of growth hormone deficiency in patients with hypogonadism treated with clomiphene citrate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.